Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., ...Daha Fazla

FUTURE ONCOLOGY, cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 35
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2217/fon-2021-0717
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.4861-4869
  • Anahtar Kelimeler: immunotherapy, kidney cancer, nivolumab, renal cell carcinoma, MANAGEMENT, EVEROLIMUS, SUNITINIB, OUTCOMES, THERAPY, BRAIN
  • İstanbul Üniversitesi Adresli: Evet

Özet

Lay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns.